23 results on '"Devresse, A."'
Search Results
2. Strategies to prevent SARS-CoV-2 transmission in hemodialysis centres across Europe—lessons for the future
- Author
-
Noordzij, Marlies, Meijers, Björn, Gansevoort, Ron T, Covic, Adrian, Duivenvoorden, Raphaël, Hilbrands, Luuk B, Hemmelder, Marc H, Jager, Kitty J, Mjoen, Geir, Nistor, Ionut, Parshina, Ekaterina, Pessolano, Giuseppina, Tuglular, Serhan, Vart, Priya, Zanoli, Luca, Franssen, Casper F M, ERACODA collaborators, Goffin, Eric, Kanaan, Nada, Labriola, Laura, Devresse, Arnaud, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, and Noordzij M., Meijers B., Gansevoort R. T., Covic A., Duivenvoorden R., Hilbrands L. B., Hemmelder M. H., Jager K. J., Mjoen G., Nistor I., et al.
- Subjects
Internal Diseases ,Urology ,Sağlık Bilimleri ,İç Hastalıkları ,Clinical Medicine (MED) ,All institutes and research themes of the Radboud University Medical Center ,UROLOGY & NEPHROLOGY ,Health Sciences ,Klinik Tıp (MED) ,KIDNEY-TRANSPLANT ,guidelines ,ÜROLOJİ VE NEFROLOJİ ,Transplantation ,Internal Medicine Sciences ,Science & Technology ,hemodialysis ,Klinik Tıp ,SARS-CoV-2 ,MORTALITY ,Dahili Tıp Bilimleri ,centre practices ,CLINICAL MEDICINE ,Urology & Nephrology ,virus transmission ,Tıp ,DIALYSIS PATIENTS ,Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11] ,Nefroloji ,Nephrology ,ERACODA ,Üroloji ,Medicine ,Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] ,Life Sciences & Biomedicine - Abstract
Background Early reports on the pandemic nature of coronavirus disease 2019 (COVID-19) directed the nephrology community to develop infection prevention and control (IPC) guidance. We aimed to make an inventory of strategies that dialysis centres followed to prevent infection with COVID-19 in the first pandemic wave. Methods We analyzed IPC measures taken by hemodialysis centres treating patients presenting with COVID-19 between 1 March 2020 and 31 July 2020 and that completed the European Renal Association COVID-19 Database centre questionnaire. Additionally, we made an inventory of guidelines published in European countries to prevent spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in dialysis centres. Results Data from 73 dialysis units located in and bordering Europe were analyzed. All participating centres implemented IPC measures to mitigate the impact of SARS-CoV-2 during the first pandemic wave. Measures mentioned most often included triage with questions before entering the dialysis ward, measuring body temperature, hand disinfection, masking for all patients and staff, and personal protective equipment for staff members. These measures were also recommended in most of the 14 guidelines that were identified in the inventory of national guidelines and were also scored as being among the most important measures by the authors of this paper. Heterogeneity existed between centres and national guidelines regarding the minimal distance between dialysis chairs and recommendations regarding isolation and cohorting. Conclusions Although variation existed, measures to prevent transmission of SARS-CoV-2 were relatively similar across centres and national guidelines. Further research is needed to assess causal relationships between measures taken and spread of SARS-CoV-2.
- Published
- 2022
3. Kidney donors with fibromuscular dysplasia, is it time to open the doors?
- Author
-
Nada Kanaan, Alexandre Persu, Arnaud Devresse, Constantina Chrysochou, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - SSS/IREC/CARD - Pôle de recherche cardiovasculaire, and UCL - (SLuc) Service de pathologie cardiovasculaire
- Subjects
Transplantation ,medicine.medical_specialty ,Kidney ,business.industry ,Fibromuscular dysplasia ,medicine.disease ,Kidney Transplantation ,Surgery ,Renal Artery ,medicine.anatomical_structure ,Nephrology ,Living Donors ,medicine ,Fibromuscular Dysplasia ,Humans ,business - Published
- 2021
4. FC070: Lumasiran for Patients with Primary Hyperoxaluria Type 1 with Impaired Kidney Function: Data from the 6-Month Analysis of the Phase 3 Illuminate-C Trial
- Author
-
Jaap Groothoff, Mini Michael, Hadas Shasha-Lavsky, John Lieske, Yaacov Frishberg, Eva Simkova, Anne-Laure Sellier-Leclerc, Devresse Arnaud, Fitsum Guebre-Egziabher, Sevcan Azime Bakkaloglu, Chebl Mourani, Rola Saqan, Richard Singer, Richard Willey, Bahru Habtemariam, Ishir Bhan, John Gansner, and Daniella Magen
- Subjects
Transplantation ,Nephrology - Abstract
BACKGROUND AND AIMS Primary hyperoxaluria type 1 (PH1) is a rare genetic disorder characterised by hepatic oxalate overproduction that leads to progressive kidney disease. As kidney function declines, oxalate elimination is compromised and plasma oxalate (POx) increases, leading to systemic oxalosis. In chronic kidney disease (CKD) stages 3b–5, elevated POx is directly related to the pathophysiology of oxalosis, and reduction of POx is a relevant clinical trial endpoint. Lumasiran, an RNA interference therapeutic designed to reduce hepatic oxalate production, is indicated for the treatment of PH1 in all age groups. Data from the ILLUMINATE-C trial (EudraCT: 2019–0 013 346-17) demonstrated substantial reductions in POx and acceptable safety in patients with PH1 with impaired kidney function, including patients on haemodialysis (HD), who received lumasiran for 6 months. In Cohorts A (no HD) and B (on HD), respectively, lumasiran led to 33.33% [95% confidence interval (95% CI): −15.16 to 81.82] and 42.43% (95% CI: 34.15–50.71) least-squares (LS) mean reductions in POx from baseline to Month 6 (the primary endpoint). Here, we present METHOD ILLUMINATE-C is an ongoing Phase 3, single-arm study with two cohorts, Cohort A (N = 6; no HD at study start) and Cohort B (N = 15; on HD). The 6-month primary analysis period is followed by an extension period (EP) of up to 54 months. Key inclusion criteria include genetically confirmed PH1, eGFR ≤ 45 mL/min/1.73 m2 and POx ≥ 20 μmol/L. Patients received weight-based dosing of subcutaneous lumasiran. Outcomes of interest for the current analysis included assessments of cardiac oxalosis using echocardiography, medullary nephrocalcinosis by kidney ultrasound, kidney stone events and burdensome symptoms of PH1. RESULTS All 21 patients [43% female; 76% white; median age 8 (range 0–59) years] completed the 6-month primary analysis period. Among patients with abnormal left ventricular ejection fraction (LVEF; abnormal defined as LVEF CONCLUSION Lumasiran treatment resulted in substantial reductions in POx in patients of all ages with PH1 and advanced kidney disease. The observations regarding cardiac measures that reflect systemic oxalosis, together with the kidney stone event and nephrocalcinosis results, are consistent with mobilisation of oxalate from systemic stores. Data on these long-term outcomes will continue to be collected and further evaluated in the EP. These results, along with previous reports from ILLUMINATE-A and ILLUMINATE-B, provide evidence supporting the effectiveness of lumasiran across the full spectrum of patients affected by PH1.
- Published
- 2022
5. FC070: Lumasiran for Patients with Primary Hyperoxaluria Type 1 with Impaired Kidney Function: Data from the 6-Month Analysis of the Phase 3 Illuminate-C Trial
- Author
-
Groothoff, Jaap, primary, Michael, Mini, additional, Shasha-Lavsky, Hadas, additional, Lieske, John, additional, Frishberg, Yaacov, additional, Simkova, Eva, additional, Sellier-Leclerc, Anne-Laure, additional, Arnaud, Devresse, additional, Guebre-Egziabher, Fitsum, additional, Azime Bakkaloglu, Sevcan, additional, Mourani, Chebl, additional, Saqan, Rola, additional, Singer, Richard, additional, Willey, Richard, additional, Habtemariam, Bahru, additional, Bhan, Ishir, additional, Gansner, John, additional, and Magen, Daniella, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Severe hypercalcaemia early after kidney transplantation in two patients with severe secondary hyperparathyroidism previously treated with etelcalcetide
- Author
-
Antoine Buemi, Laura Labriola, Jean-Michel Pochet, Guillaume Dachy, Valentine Gillion, Arnaud Devresse, Michel Jadoul, Nada Kanaan, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, and UCL - (SLuc) Service de chirurgie et transplantation abdominale
- Subjects
kidney transplant ,Parathyroidectomy ,medicine.medical_specialty ,Cinacalcet ,Hypercalcaemia ,medicine.medical_treatment ,030232 urology & nephrology ,Urology ,Exceptional Cases ,parathyroidectomy ,03 medical and health sciences ,0302 clinical medicine ,Biopsy ,medicine ,030212 general & internal medicine ,AcademicSubjects/MED00340 ,Kidney transplantation ,Etelcalcetide ,Transplantation ,etelcalcetide ,medicine.diagnostic_test ,business.industry ,calcimimetics ,hypercalcaemia ,medicine.disease ,haemodialysis ,Nephrology ,Secondary hyperparathyroidism ,Hemodialysis ,business ,medicine.drug - Abstract
Cinacalcet and, more recently, etelcalcetide revolutionized the treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney transplant (KT) usually improves CKD–MBD. However, a significant proportion of KT recipients have high serum calcium levels, not requiring any treatment. We report two patients previously treated with etelcalcetide who developed severe (>3.3 mmol/L) hypercalcaemia in the early post-KT course, requiring parathyroidectomy. Pathological studies showed parathyroid adenomas and hyperplasia. One patient had a graft biopsy showing numerous intratubular calcium phosphate crystals. These observations should prompt pharmacovigilance studies and careful follow-up of KT recipients previously treated with etelcalcetide.
- Published
- 2021
7. An Outsider’s View from Inside
- Author
-
Marie-Sophie Devresse and Damien Scalia
- Subjects
Sociology and Political Science ,Political science ,Law - Abstract
Acquittal in international criminal law has long been disregarded by the governing bodies of international criminal courts. However, the acquittal exposes constitutive (and constituent) components of this very body of law. The authors draw conclusions from semi-directive interviews with (acquitted and condemned) people tried by the ad hoc tribunals. Their approach creates an opportunity to highlight and comprehend — from the perspective of the acquitted individual — the failures of the functioning of international criminal justice, which is focused on the idea of guilt. Moreover, this research shows how the position of tried individuals affects their perception and acceptance of international criminal law.
- Published
- 2019
8. How to manage cigarette smoking in kidney transplant candidates and recipients?
- Author
-
Arnaud Devresse, Arnaud Robert, Nada Kanaan, Sophie Gohy, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (SLuc) Service de pneumologie, UCL - (SLuc) Service de néphrologie, and UCL - (SLuc) Centre de référence pour la mucoviscidose
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Population ,030232 urology & nephrology ,Psychological intervention ,kidney transplantation ,030204 cardiovascular system & hematology ,bupropion ,Kidney transplant ,nicotine replacement therapy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,medicine ,Intensive care medicine ,education ,Varenicline ,AcademicSubjects/MED00340 ,Kidney transplantation ,Bupropion ,education.field_of_study ,Transplantation ,business.industry ,Nicotine replacement therapy ,medicine.disease ,CKJ Review ,smoking cessation ,varenicline ,chemistry ,Nephrology ,Smoking cessation ,business ,medicine.drug - Abstract
Tobacco smoking is a frequent problem affecting many kidney transplant (KT) candidates and recipients. The negative impact of active smoking on KT outcomes has been demonstrated. Consequently, most guidelines strongly recommend quitting smoking before considering kidney transplantation. However, nicotine addiction is a complex multifactorial disease and only 3–5% of the patients who try to quit by themselves achieve prolonged abstinence. Smoking cessation programmes (SCPs) have proven their efficacy in the general population to increase the rate of quitting and should therefore be proposed to all smoking KT candidates and recipients. Nevertheless, SCPs have not been evaluated in the KT field and not all KT centres have easy access to these programmes. In this work, we aim to review the current knowledge on the subject and provide an overview of the available interventions to help smoking patients quit. We detail non-pharmaceutical and pharmaceutical approaches and discuss their use in KT candidates and recipients.
- Published
- 2021
9. High response rate to BNT162b2 mRNA COVID-19 vaccine among self-care dialysis patients
- Author
-
Benoit Kabamba, Leila Belkhir, Anaïs Scohy, Nada Kanaan, Jean Cyr Yombi, Arnaud Devresse, Johann Morelle, Julien De Greef, Hélène Georgery, Eric Goffin, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - SSS/IREC/LTAP - Louvain Centre for Toxicology and Applied Pharmacology, UCL - SSS/IREC/MBLG - Pôle de Microbiologie médicale, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de microbiologie, UCL - (SLuc) Service de médecine interne générale, UCL - (SLuc) Service d'hématologie, and UCL - (SLuc) Service de néphrologie
- Subjects
Response rate (survey) ,Transplantation ,Messenger RNA ,medicine.medical_specialty ,2019-20 coronavirus outbreak ,immunosuppression ,Coronavirus disease 2019 (COVID-19) ,business.industry ,SARS-CoV-2 ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Vaccination ,Self-care dialysis ,COVID-19 ,Dialysis patients ,Home Hemodialysis ,Nephrology ,Internal medicine ,medicine ,Self care ,business ,AcademicSubjects/MED00340 ,Letter to the Editor ,Peritoneal Dialysis - Abstract
Coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is particularly life threatening in patients with kidney failure under dialysis, with mortality rate at 28 days of 21.2% in the ERA-EDTA registry and 25% in the ERACODA (European Renal Association COVID-19 Database) database. [...]
- Published
- 2021
10. High response rate to BNT162b2 mRNA COVID-19 vaccine among self-care dialysis patients
- Author
-
Georgery, Hélène, primary, Devresse, Arnaud, additional, Yombi, Jean-Cyr, additional, Belkhir, Leila, additional, De Greef, Julien, additional, Scohy, Anais, additional, Kanaan, Nada, additional, Kabamba, Benoit, additional, Morelle, Johann, additional, and Goffin, Eric, additional
- Published
- 2021
- Full Text
- View/download PDF
11. MO939RECURRENCE AND OUTCOME OF ANTI-GLOMERULAR BASEMENT MEMBRANE GLOMERULONEPHRITIS AFTER KIDNEY TRANSPLANTATION: A BELGIAN MULTICENTER STUDY
- Author
-
Coche, Sophie, primary, Sprangers, Ben, additional, Van Laecke, Steven, additional, Weekers, Laurent, additional, De Meyer, Vicky, additional, Hellemans, Rachel, additional, Castanares, Diego, additional, Ameye, Heleen, additional, Goffin, Eric Jean, additional, Demoulin, Nathalie, additional, Gillion, Valentine, additional, Mourad, Michel, additional, Darius, Tom, additional, Antoine, Buemi, additional, Arnaud, Devresse, additional, and Kanaan, Nada, additional
- Published
- 2021
- Full Text
- View/download PDF
12. COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration
- Author
-
Hilbrands, L. B., Duivenvoorden, R., Vart, P., Franssen, C. F. M., Hemmelder, M. H., Jager, K. J., Kieneker, L. M., Noordzij, M., Pena, M. J., de Vries, H., Arroyo, D., Covic, A., Crespo, M., Goffin, E., Islam, M., Massy, Z. A., Montero, N., Oliveira, J. P., Munoz, A. R., Sanchez, J. E., Sridharan, S., Winzeler, R., Gansevoort, R. T., van der Net, Jeroen B., Marie, Essig, Peggy W, G du Buf-Vereijken, Betty van Ginneken, Nanda, Maas, Liffert, Vogt, van Jaarsveld, Birgit C., Bemelman, Frederike J., Farah, Klingenberg-Salahova, Frederiek, Heenan-Vos, Vervloet, Marc G., Azam, Nurmohamed, Daniel, Abramowicz, Sabine, Verhofstede, Omar, Maoujoud, Jana, Fialova, Edoardo, Melilli, Alex, Favà, Cruzado, Josep M., Joy, Lips, Maaike, Hengst, Ryszard, Gellert, Andrzej, Rydzewski, Alferes, Daniela G., Ivan, Rychlik, Zakharova, Elena V., Patrice Max Ambuehl, Fanny, Lepeytre, Clémentine, Rabaté, Guy, Rostoker, Sofia, Marques, Tijana, Azasevac, Dajana, Katicic, Marc ten Dam, Thilo, Krüger, Susan J, J Logtenberg, Lutz, Fricke, L van Zanen, A, Jeroen J, P Slebe, Delphine, Kemlin, Jacqueline van de Wetering, Jaromir, Eiselt, Lukas, Kielberger, El-Wakil, Hala S., Samar Abd ElHafeez, Christina, Canal, Carme, Facundo, Ramos, Ana M., Alicja, Debska-Slizien, Nicoline M, H Veldhuizen, Stylianos, Panagoutsos, Irina, Matceac, Ionut, Nistor, Monica, Cordos, J H, M Groeneveld, Marjolijn van Buren, Fritz, Diekmann, Ferreira, Ana C., Augusto Cesar, S. Santos Jr., Carlos, Arias-Cabrales, Laura, Llinàs-Mallol, Anna, Buxeda, Carla Burballa Tàrrega, Dolores, Redondo-Pachon, Maria Dolores Arenas Jimenez, Hofstra, Julia M., Antonio, Franco, Rodríguez-Ferrero, María L., Sagrario Balda Manzanos, Gabriel de Arriba, Haridian Sosa Barrios, R., Karlijn, Bartelet, Erol, Demir, Daan A M, J Hollander, Angele, Kerckhoffs, Stefan, Büttner, Aiko P, J de Vries, Soufian, Meziyerh, Danny van der Helm, Marlies, Reinders, Hanneke, Bouwsma, Kristina, Petruliene, Sharon, Maloney, Iris, Verberk, Marina Di Luca, Tuğlular, Serhan Z., Charles, Beerenhout, Luik, Peter T., Julia, Kerschbaum, Martin, Tiefenthaler, Bruno, Watschinger, Adema, Aaltje Y., Stepanov, Vadim A., Zulkarnaev, Alexey B., Kultigin, Turkmen, Bonucchi, Decenzio, Anselm, Fliedner, Hitoshi, Miyasato, Anders, Åsberg, Geir, Mjoen, Stefano, Pini, Consuelo de Biase, Anne Els van de Logt, Rutger, Maas, Olga, Lebedeva, Veronica, Lopez, Louis J, M Reichert, Jacobien, Verhave, Denis, Titov, Parshina, Ekaterina V., Liesbeth E, A van Gils-Verrij, Charlotte J, R de Bruin, Harty, John C., Marleen, Meurs, Marek, Myslak, Yuri, Battaglia, Paolo, Lentini, Edwin den Deurwaarder, Hormat, Rahimzadeh, Marcel, Schouten, Cabezas-Reina, Carlos J., Anabel, Diaz-Mareque, Armando, Coca, Björn K, I Meijers, Maarten, Naesens, Dirk, Kuypers, Bruno, Desschans, Annelies, Tonnerlier, Wissing, Karl M., Ivana, Dedinska, Giuseppina, Pessolano, van der Sande, Frank M., Maarten H, L Christiaans, Ilaria, Gandolfini, Umberto, Maggiore, Nada, Kanaan, Laura, Labriola, Arnaud, Devresse, Shafi, Malik, Berger, Stefan P., Esther, Meijer, Sanders, Jan Stephan F., Jadranka Buturović Ponikvar, Abrahams, Alferso C., Molenaar, Femke M., van Zuilen, Arjan D., S C, A Meijvis, Helma, Dolmans, Luca, Zanoli, Carmelita, Marcantoni, Esposito, Pasquale, Jean-Marie, Krzesinski, Jean Damacène Barahira, Maurizio, Gallieni, Gianmarco, Sabiu, Paloma Leticia Martin-Moreno, Gabriele, Guglielmetti, Gabriella, Guzzo, Luik, Antinus J., Willi H, M van Kuijk, Lonneke W, H Stikkelbroeck, Hermans, Marc M. H., Laurynas, Rimsevicius, Marco, Righetti, Nicole Heitink-ter Braak, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, Groningen Kidney Center (GKC), Cardiovascular Centre (CVC), Clinical sciences, Nephrology, Medical Informatics, ACS - Pulmonary hypertension & thrombosis, APH - Aging & Later Life, APH - Global Health, and APH - Quality of Care
- Subjects
Male ,Databases, Factual ,Kidney Failure, Chronic/mortality ,medicine.medical_treatment ,030232 urology & nephrology ,Waiting Lists/mortality ,Kidney Failure ,0302 clinical medicine ,Risk Factors ,Epidemiology ,Kidney Transplantation/mortality ,80 and over ,Medicine ,030212 general & internal medicine ,Prospective Studies ,Chronic ,Prospective cohort study ,Kidney transplantation ,Aged, 80 and over ,Renal Dialysis/mortality ,SARS-CoV-2/isolation & purification ,Hazard ratio ,Age Factors ,Middle Aged ,Prognosis ,Europe ,Survival Rate ,Nephrology ,COVID-19 ,Dialysis ,Kidney ,Mortality ,Transplantation ,Adult ,Aged ,Female ,Humans ,Kidney Failure, Chronic ,Kidney Transplantation ,Renal Dialysis ,SARS-CoV-2 ,Waiting Lists ,Hemodialysis ,medicine.medical_specialty ,kidney ,Europe/epidemiology ,03 medical and health sciences ,Databases ,All institutes and research themes of the Radboud University Medical Center ,Internal medicine ,AcademicSubjects/MED00340 ,Survival rate ,Factual ,COVID-19/chemically induced ,business.industry ,Original Articles ,medicine.disease ,mortality ,Renal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11] ,dialysis ,Renal disorders Radboud Institute for Health Sciences [Radboudumc 11] ,business ,transplantation - Abstract
Background. Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population. Methods. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality. Results. Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 ± 13 and 67 ± 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3–30.2%] in kidney transplant and 25.0% (95% CI 20.2–30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59–1.10, P = 0.18]. In the subset of dialysis patients who were a candidate for transplantation (n = 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation Conclusions. The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.
- Published
- 2020
- Full Text
- View/download PDF
13. How to manage cigarette smoking in kidney transplant candidates and recipients?
- Author
-
Devresse, Arnaud, primary, Gohy, Sophie, additional, Robert, Arnaud, additional, and Kanaan, Nada, additional
- Published
- 2021
- Full Text
- View/download PDF
14. Severe hypercalcaemia early after kidney transplantation in two patients with severe secondary hyperparathyroidism previously treated with etelcalcetide
- Author
-
Dachy, Guillaume, primary, Pochet, Jean-Michel, additional, Labriola, Laura, additional, Buemi, Antoine, additional, Gillion, Valentine, additional, Jadoul, Michel, additional, Kanaan, Nada, additional, and Devresse, Arnaud, additional
- Published
- 2021
- Full Text
- View/download PDF
15. SO058IGG4-RELATED KIDNEY DISEASE : A FRENCH NATIONWIDE RETROSPECTIVE COHORT STUDY
- Author
-
Belliere Julie, Duquennoy Simon, Eve Vilaine, Stanislas Faguer, Claire Cartery, Audard Vincent, Jean-Michel Halimi, Dominique Joly, Mathilde Nouvier, Goumri Nabila, Titeca Dimitri, Marie-Noëlle Peraldi, Legendre Mathieu, Devresse Arnaud, Anis Chaba, Snanoudj Renaud, Olivier Thaunat, Mohamad Zaidan, Boffa Jean Jacques, Thierry Petitclerc, Eric Daugas, Jonathan M. Chemouny, Karras Alexandre, Hanouna Guillaume, and Hanf William
- Subjects
Transplantation ,Pediatrics ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Medical record ,Renal function ,Retrospective cohort study ,medicine.disease ,Kidney imaging ,Nephrology ,Immunoglobulin g4 ,medicine ,Middle-aged adult ,Renal biopsy ,business ,Kidney disease - Abstract
Background and Aims IgG4 disease is a systemic fibroinflammatory disorder that may affect virtually any organ. IgG4-related kidney disease (IgG4-RKD) is a major manifestation, occurring in almost one third of patient. The present study addresses the diagnosis, management and outcome of French patients with IgG4-RKD. Method We conducted a retrospective observational study including patients with renal impairment due to IgG4-RKD from 32 centers. Clinical, biological, and imaging data, as well as management modalities and outcome, were retrieved from medical records. Results 74 patients, 64 males and 10 females, were diagnosed with IgG4-RKD between 1997 and 2019 and were included in the present study. The mean age at diagnosis was 65.2 ± 15-year-old. Renal involvement was present at diagnosis in 63% of cases. Nine (12%) patients had isolated renal involvement, whereas extra-renal involvement included retroperitoneal fibrosis (20%), auto-immune pancreatitis (49%), cholangitis (27%), and lung disease (22%). Renal imaging lesions were observed in 48 (64%) patients, and included renal hypertrophy, patchy lesions and pseudo-tumor solitary renal lesion. PET-CT scan was performed in 47 (65%) patients and showed hypermetabolic renal lesion(s) in 36% of cases. The presence of extra-renal hypermetabolic lesions was observed in 35 cases (74%). 43 %, 25% and 14% of patients presented with AKI, AKI-on-CKD, and isolated CKD, respectively. The mean serum creatinine level at diagnosis was 244 ± 140 µmol/L, corresponding to an eGFR of 69 ± 22ml/min/1.73m. Urinary sediment was most often bland. Mean urine protein-to-creatinine ratio was 1.27 g/g. of note, 26% of patients had more than 1 g/g. 82% of patients underwent a kidney biopsy showing tubulointerstitial involvement in all cases, 12 (16%) had additional glomerular involvement, mainly membranous nephropathy. The major additional laboratory abnormalities included polyclonal hypergammaglobulinemia, and increased serum IgG4 increase in 83% and 86%, respectively. Complement levels were decreased in 27 (37%) patients. Two patients were lost for follow-up and 69 patients were treated with corticosteroid therapy in 66 (89%) patients and 10 received Rituximab as first line therapy. The mean duration of follow-up was 28.8 ± 30 months. During follow-up, 22 (30%) patients relapsed, while 45 (62%) patients had persistent CKD at last follow-up, with a mean eGFR of 47±27 ml/min/1.73m. Seven (9%) patients progressed to ESRD and 7 died. A significant response was achieved in 46 (62%) patients. Patients who received steroids higher than 0.5mg/kg/day had lower serum IgG4 levels (1.8 g/l versus 5.7 g/l, p=0.007) at last follow up but there was no significant difference observed in terms of renal function between the two groups (45.5 vs 48.8 ml/min/1.73m, p= 0.72). By univariate analysis, predictors of relapse were low C3 or C4 serum level (p=0.01), ANCA positivity (p= 0.02), renal radiological lesions (p=0.05). At last follow-up the eGFR was worse in patients with a serum creatinine diagnosis greater than 300 µmol/L (30.25 vs 57 ml/min/1.73m p=0.0001) and more progressed to ESRD (p=0.03). Conclusion IgG4-RKD has been recently described and may affect middle-aged males. The disease presents as tubulointerstitial nephritis with glomerular involvement in 16% of cases. Disease response to corticosteroid therapy is favorable but is characterized by a high rate of relapses and a significant risk of persistent CKD in the majority of patient. Risk of ESRD and death in almost 20% of patients.
- Published
- 2020
16. SO058IGG4-RELATED KIDNEY DISEASE : A FRENCH NATIONWIDE RETROSPECTIVE COHORT STUDY
- Author
-
Chaba, Anis, primary, Zaidan, Mohamad, primary, Jean Jacques, BOFFA, primary, Alexandre, KARRAS, primary, Vincent, Audard, primary, RENAUD, SNANOUDJ, primary, Thaunat, Olivier, primary, NOUVIER, Mathilde, primary, Arnaud, DEVRESSE, primary, Joly, Dominique, primary, Halimi, Jean Michel, primary, CARTERY, CLAIRE, primary, Daugas, Eric, primary, Peraldi, Marie-Noelle, primary, Mathieu, LEGENDRE, primary, Julie, BELLIERE, primary, Faguer, Stanislas, primary, Dimitri, TITECA, primary, William, HANF, primary, Petitclerc, Thierry, primary, Guillaume, HANOUNA, primary, Chemouny, Jonathan, primary, Nabila, GOUMRI, primary, Simon, DUQUENNOY, primary, and Vilaine, Eve, primary
- Published
- 2020
- Full Text
- View/download PDF
17. Baseline graft status is a critical predictor of kidney graft failure after diarrhoea
- Author
-
Fanny Lanternier, Lise Morin, Florence Aulagnon, Frank Martinez, L Bererhi, Renaud Snanoudj, Adel A Aidoud, Rebecca Sberro-Soussan, Xavier Lebreton, Lucile Amrouche, Anne Scemla, Dany Anglicheau, Jean-Luc Taupin, Véronique Avettand-Fenoel, Julien Zuber, Olivier Lortholary, O. Aubert, Arnaud Devresse, Claire Tinel, Christophe Legendre, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, and UCL - (SLuc) Service de néphrologie
- Subjects
Adult ,Diarrhea ,Graft Rejection ,Male ,medicine.medical_specialty ,Time Factors ,030232 urology & nephrology ,Renal function ,030230 surgery ,Gastroenterology ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Risk Factors ,Internal medicine ,medicine ,Humans ,Kidney transplantation ,Retrospective Studies ,Kidney ,Transplantation ,business.industry ,Incidence ,Graft Survival ,Hazard ratio ,Acute kidney injury ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Kidney Transplantation ,medicine.anatomical_structure ,Nephrology ,Kidney Failure, Chronic ,Female ,France ,medicine.symptom ,business ,Glomerular Filtration Rate - Abstract
Background Diarrhoea is one of the most frequent complications after kidney transplantation (KT). Non-infectious diarrhoea has been associated with reduced graft survival in kidney transplant recipients. However, the risk factors for renal allograft loss following diarrhoea remain largely unknown. Methods Between January 2010 and August 2011, 195 consecutive KT recipients who underwent standardized microbiological workups for diarrhoea at a single centre were enrolled in this retrospective study. Results An enteric pathogen was readily identified in 91 patients (47%), while extensive microbiological investigations failed to find any pathogen in the other 104. Norovirus was the leading cause of diarrhoea in these patients, accounting for 30% of the total diarrhoea episodes. The baseline characteristics were remarkably similar between non-infectious and infectious diarrhoea patients, with the exception that the non-infectious group had significantly lower graft function before diarrhoea (P = 0.039). Infectious diarrhoea was associated with a longer duration of symptoms (P = 0.001) and higher rates of acute kidney injury (P = 0.029) and hospitalization (P Conclusion Our study shows that pre-existing conditions (re-transplantation, chronic graft dysfunction and late occurrence) determine the primary functional long-term consequences of post-transplant diarrhoea.
- Published
- 2019
18. FP794HEPATITIS C Virus can be eliminated from a prevalent kidney transplant recipient population : a single centre study in the direct-acting antivirals era
- Author
-
Devresse, Arnaud, Delire, Bénédicte, Lazarus, Jeffrey V, Kabamba-Mukadi, Benoît, De Meyer, Martine, Mourad, Michel, Buemi, Antoine, Darius, Tom, Goffin, Eric, Jadoul, Michel, Kanaan, Nada, 56th ERA-EDTA Congress, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, UCL - (SLuc) Service de néphrologie, UCL - (SLuc) Service de chirurgie et transplantation abdominale, and UCL - (SLuc) Service de microbiologie
- Subjects
education.field_of_study ,Transplantation ,business.industry ,Hepatitis C virus ,Population ,Geographic population ,medicine.disease_cause ,DIRECT ACTING ANTIVIRALS ,Virology ,Virus ,Kidney transplant recipient ,Single centre ,Nephrology ,medicine ,education ,business - Published
- 2019
19. FP794HEPATITIS C VIRUS CAN BE ELIMINATED FROM A PREVALENT KIDNEY TRANSPLANT RECIPIENT POPULATION: A SINGLE-CENTRE STUDY IN THE DIRECT-ACTING ANTIVIRALS ERA
- Author
-
Devresse, Arnaud, primary, Delire, Bénédicte, additional, Lazarus, Jeffrey V, additional, Kabamba, Benoit, additional, De Meyer, Martine, additional, Mourad, Michel, additional, Buemi, Antoine, additional, Darius, Tom, additional, Goffin, Eric, additional, Jadoul, Michel, additional, and Kanaan, Nada, additional
- Published
- 2019
- Full Text
- View/download PDF
20. An Outsider’s View from Inside
- Author
-
Devresse, Marie-Sophie, primary and Scalia, Damien, additional
- Published
- 2019
- Full Text
- View/download PDF
21. Baseline graft status is a critical predictor of kidney graft failure after diarrhoea
- Author
-
Devresse, Arnaud, primary, Morin, Lise, primary, Aulagnon, Florence, primary, Taupin, Jean-Luc, primary, Scemla, Anne, primary, Lanternier, Fanny, primary, Aubert, Olivier, primary, Aidoud, Adel A, primary, Lebreton, Xavier, primary, Sberro-Soussan, Rebecca, primary, Snanoudj, Renaud, primary, Amrouche, Lucile, primary, Tinel, Claire, primary, Martinez, Frank, primary, Bererhi, Lynda, primary, Anglicheau, Dany, primary, Lortholary, Olivier, primary, Legendre, Christophe, primary, Avettand-Fenoel, Véronique, primary, and Zuber, Julien, primary
- Published
- 2019
- Full Text
- View/download PDF
22. Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
- Author
-
François Roman, Pierre-Yves Devresse, Marc De Meulemeester, Mamadou Dramé, Stéphane Heijmans, Paul Gillard, Giancarlo Icardi, Paul Reynders, Didier Giet, and Etienne Demanet
- Subjects
Male ,Influenza vaccine ,medicine.medical_treatment ,medicine.disease_cause ,Major Articles and Brief Reports ,Influenza, Human ,Pandemic ,Influenza A virus ,Humans ,Immunology and Allergy ,Medicine ,Live attenuated influenza vaccine ,Aged ,Aged, 80 and over ,Influenza A Virus, H5N1 Subtype ,business.industry ,Immunogenicity ,Middle Aged ,Virology ,Influenza A virus subtype H5N1 ,Vaccination ,Hemagglutinins ,Infectious Diseases ,Influenza Vaccines ,Viruses ,Immunology ,Female ,business ,Adjuvant - Abstract
The past decade has seen unprecedented preparation for a human influenza pandemic. Until the 2009 outbreak of human cases of (swine) influenza A (H1N1), the avian influenza H5N1 virus was considered a potential cause of a human influenza pandemic. The H5N1 virus remains a considerable threat to human health, and it is important that pandemic preparedness planning for an outbreak continues. Moreover, vaccine development strategies for a potential H5N1 pandemic can guide development of vaccines to combat the 2009/10 H1N1 pandemic and other future potential influenza pandemics. Development of an influenza vaccine that induces a cross-reactive immune response is a key component of a pandemic preparedness strategy. Such a vaccine is likely to prime the immune system to mount a rapid response to vaccination with a drifted strain and/or to infection and may be used before the onset of a pandemic or in its early stages. Even partial cross-protection may have a considerable impact on infection rates during early pandemic stages [1, 2]. The vaccine must provide a high and long-lasting immune response at a relatively low antigen dose, because the need for a high dose would exhaust the limited global production capacity for influenza antigen. Formulation of pandemic vaccines using adjuvants to stimulate a robust immune response is an important approach to reducing the antigen dose and eliciting a cross-reactive response [3]. An H5N1 pandemic vaccine based on the A/Vietnam/1194/2004 clade 1 strain is licensed to be used in the event of an imminent H5N1 pandemic. The vaccine is adjuvanted with AS03A, a novel tocopherol oil-in-water emulsion-based adjuvant system (11.86 mg of tocopherol). It is licensed to be delivered via a schedule of 2 injections administered 3 weeks apart [4]. In a study in adults aged 18-60 years, the lowest dose investigated (3.75 μg hemagglutinin [HA]) elicited immune responses against the vaccine strain that met all US Center for Biologics Evaluation and Research and European Committee for Human Medicinal Products (CHMP) immunologic licensure criteria [5]. Much higher doses were needed to induce a moderate immune response with a nonadjuvanted H5N1 split-virus vaccine [6], indicating that adjuvantation with AS03A allows successful dose sparing. In addition, the vaccine has been shown to induce a cross-reactive immune response (hemagglutination inhibition [HI]) and neutralizing antibodies and CD4 T cell–mediated immune response) against drifted clade 2 H5N1 strains [5, 7–10] An acceptable safety and reactogenicity profile has been demonstrated [5, 8, 11]. Studies with seasonal influenza vaccines suggest that the reduced immune response to vaccination in elderly populations is due – at least in part – to immunosenescence [12]. It is possible that elderly people may therefore need additional or higher doses. This study aimed to assess the immune response in an elderly population to 2 single or 2 double doses of the AS03A-adjuvanted H5N1 pandemic vaccine, administered 21 days apart, compared with the same dosage and schedule without the adjuvant system.
- Published
- 2011
23. Immunogenicity Profile of a 3.75-μg Hemagglutinin Pandemic rH5N1 Split Virion AS03A-Adjuvanted Vaccine in Elderly Persons: A Randomized Trial
- Author
-
Heijmans, Stéphane, primary, De Meulemeester, Marc, additional, Reynders, Paul, additional, Giet, Didier, additional, Demanet, Etienne, additional, Devresse, Pierre-Yves, additional, Icardi, Giancarlo, additional, Dramé, Mamadou, additional, Roman, François, additional, and Gillard, Paul, additional
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.